123971-42-6 Usage
General Description
2-Thiazolecarboxylic acid, 4-(4-methoxyphenyl)- is a chemical compound with the molecular formula C12H9NO3S. It belongs to the thiazolecarboxylic acid family and contains a thiazole ring with a carboxylic acid group and a 4-(4-methoxyphenyl) substituent. 2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)- has various potential applications, including as a pharmaceutical intermediate or building block for the synthesis of other organic compounds. It may also possess biological activity and has been studied for its potential therapeutic properties. Additionally, it may be used in research and development in the field of organic chemistry and drug discovery.Overall, 2-Thiazolecarboxylic acid, 4-(4-methoxyphenyl)- is a versatile chemical compound with potential applications in pharmaceuticals, research, and development.
Check Digit Verification of cas no
The CAS Registry Mumber 123971-42-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,9,7 and 1 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 123971-42:
(8*1)+(7*2)+(6*3)+(5*9)+(4*7)+(3*1)+(2*4)+(1*2)=126
126 % 10 = 6
So 123971-42-6 is a valid CAS Registry Number.
123971-42-6Relevant articles and documents
MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF
-
Page/Page column 115, (2017/02/24)
Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.